Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment

Leukemia

Volumn 14, Issue 7, 2000, Pages 1266-1275

  Belaud Rotureau, M A ^a,b   Durrieu, F ^a   Labroille, G ^b   Lacombe, F ^a,c   Fitoussi, O ^a   Agape, P ^a   Marit, G ^a,b   Reiffers, J ^a   Belloc, F ^a,b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS Bordeaux Segalen University   (France)

Author keywords

Anthracycline; Apoptosis; Caspase; Fas; Leukemia

Indexed keywords

ANTHRACYCLINE; CASPASE; DAUNORUBICIN; FAS ANTIGEN; GLYCOPROTEIN P; IDARUBICIN; PHOSPHATIDYLSERINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CANCER REGRESSION; CELL CULTURE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

EID: 0033934637     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401803     Document Type: Article

References (49)

1. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
2. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
3. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
4. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORTI/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-815.
5. Muzzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M. Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
6. Medema IP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME. FLICE is activated by association with the Cd95 death-inducing signaling complex (DISC). EMBO J 1997; 16: 2794-2804.
7. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
8. Solary E, Micheau O, Dimanche-Boitrel MT, Martin F. Role of the Fas/Fas-L system in the immune response to tumors and the resistance to cytotoxic drugs. Bull Cancer 1998; 85: 685-694.
9. Dirks W, Schöne S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (Fas/APO-1) in leukemia-lymphoma tumour lines. Br J Haematol 1997; 96: 584-593.
10. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowirz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-4798.
11. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-1861.
12. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas-ligand interactions. Blood 1997; 90: 935-943.
13. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 1997; 79: 1180-1189.
14. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-2596.
15. Nakamura S, Takeshirna M, Nakamura Y, Ohtake S, Matsuda T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 1997; 17: 173-179.
16. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subcytotoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 1996; 62: 232-291.
17. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-789.
18. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997; 80: 42-49.
19. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 1993; 53: 1845-1852.
20. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 1993; 46: 375-382.
21. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol 1994; 46: 901-908.
22. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
23. Vial JP, Belloc F, Dumain P, Besnard S, Lacombe F, Boisseau MR, Reiffers J, Bernard P. Study of the apoptosis induced in vitro by antitumoral drugs on leukemic cells. Leukemia Res 1997; 21: 163-172.
24. Durrieu F, Belloc F, Lacoste L, Dumain P, Chabrol J, Dachary-Prigent J, Morjani H, Boisseau MR, Reiffers J, Bernard P, Lacombe F. Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they are ingested by phagocytes. Exp Cell Res 1998; 240: 165-175.
25. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-I/Fas) system in drug-resistant cells. Leukemia 1997; 11: 1833-1841.
26. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
27. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
28. Droin N, Dubrez L, Eymin B, Renvoizé C, Breard J, Dimanche-Boitrel MT, Solary E. Upregulation CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene 1998; 16: 2385-2394.
29. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203-1211.
30. Praet M, Stryckmans P, Ruysschaert JM. Cellular uptake, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochem Pharmacol 1996; 51: 1341-1348.
31. Goltesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-425.
32. Frankfurt OS, Seckinger D, Sugarbaker EV. Pleiotropic drug resistance and survival advantage in leukemia cells with diminished apoptotic response. Int J Cancer 1994; 59: 217-224.
33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-458.
34. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard P. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886.
35. Belaud-Rotureau MA, Lacombe F, Durrieu F, Vial JP, Lacoste C, Bernard P, Belloc F. Ceramide-induced apoptosis occurs independently of caspases and is decreased by leupeptin. Cell Death Differ 1999; 6: 788-795.
36. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishihashi K, Kodama M, Iwahashi M, Arima T, Akiyama S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-873.
37. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82: 349-352.
38. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-698.
39. Zubrod CG. Treatment of the acute leukemias. Cancer Res 1967; 27: 2557-2560.
40. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993; 17: 219-251.
41. Borchmann P, Hubel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80-03.
42. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
43. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 1999; 94: 1086-1099.
44. Coon JS, Wang Y, Bines SD, Markham PN, Chong ASF, Gebel HM. Multidrug resistance activity in human lymphocytes. Hum Immunol 1991; 32: 134-140.
45. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992; 80: 2729-2734.
46. Klimeckj WT, Furscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
47. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-1754.
48. Raymond M, Gros P, Whiteway M, Thomas DY. Functional complementation of yeast ste6 by mammalian multidrug resistance mdr gene. Science 1992; 256: 232-234.
49. Durrieu F, Belaud-Rotureau MA, Lacombe F, Dumain P, Reiffers J, Boisseau MR, Bernard P, Belloc F. Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic tell lines. Cytometry 1999; 36: 140-149.